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Summary
The PGD2 metabolite 15-deoxy-delta12,14 PGJ2 (15d-PGJ2), a potent peroxisome proliferator-activated receptor  (PPAR) activator, has
recently received attention for its potential antiinflammatory effects, but its effect on the cyclooxygenase-2 (COX-2) production is still under
debate. We investigated the effect of 15d-PGJ2 on COX-2 and prostaglandin E2 (PGE2) production in the absence or the presence of
interleukin-1 (IL-1) in human osteoarthritic chondrocytes.
Data showed that, as expected, IL-1 induced both COX-2 and PGE2 production. The addition of 15d-PGJ2 completely blocked (by 93%)
the IL-1-induced PGE2 synthesis, whereas COX-2 level was only partially reduced (by 72%). Interestingly in the absence of any COX-2
inducer, 15d-PGJ2 up-regulated COX-2 expression without concomitant elevation of PGE2 synthesis. This study showed that the PPAR
agonist, 15d-PGJ2, exerts a dual effect on COX-2 production. The mechanisms by which 15d-PGJ2 favors COX-2 production will be
discussed. © 2002 OsteoArthritis Research Society International. Published by Elsevier Science Ltd. All rights reserved.
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Abbreviations: 15d-PGJ2, 15-deoxy-delta12,14 PGJ2; AP-1, activator protein-1; AA, arachidonic acid; cAMP, CAMP dependent protein
kinase; COX, cyclooxygenase; DMEM, Dulbecco Modified Eagle Medium; IL-1, interleukin-1β; NF-B, nuclear factor-kappa B; LPS,
lipopolysaccharide; NO, nitric oxide; PPRE, peroxisome proliferator response element; PPAR, peroxisome proliferator-activated receptor
gamma; PLA2, cytoplasmic phospholipase A2; PGE2, prostaglandin E2; SDS, sodium dodecyl sulfate; TNF-, tumor necrosis factor alpha.Introduction
Cartilage homeostasis is tightly regulated and is the result
of a balance between both anabolic and catabolic factors.
Prostaglandins play a significant role not only in normal
joint physiology but also in the pathogenesis of joint dis-
orders and probably mediate some of the actions of
interleukin-1 (IL-1) and tumor necrosis factor (alpha)
(TNF-) on these tissues1. Cyclo-oxygenase (COX) is the
key enzyme in prostaglandin synthesis, and two isoforms
have been identified, COX-1 and -2. COX-1 is expressed
constitutively in many tissues, whereas COX-2 is largely
absent but induced upon stimulation by a wide array of
stimuli including proinflammatory cytokines. Selective
COX-2 inhibitors are effective antiinflammatory drugs and
are widely used to treat arthritis.
Peroxisome proliferator-activated receptor gamma
(PPAR) is a member of the nuclear hormone receptor
superfamily that includes the estrogen, thyroid hormone
and glucocorticoid receptors2. Recent data showed that
PPAR ligands modulate inflammatory responses. In this
context, the PGD2 metabolite 15-deoxy-delta12,14 PGJ2845(15d-PGJ2), a potent natural ligand for the PPAR3,4 was
shown to inhibit the production of several inflammatory
mediators by monocytes/macrophages5,6. Recently, we
and others have shown that 15d-PGJ2 inhibits IL-1-
induced collagenase-3 and nitric oxide (NO) production as
well as proteoglycan degradation7,8 in chondrocytes and
collagenase-1 production in synoviocytes9. Therefore, the
PPAR pathway may constitute an interesting therapeutic
target in the treatment of arthritic diseases.
In this study, we investigated the effect of 15d-PGJ2 on
COX-2 expression and prostaglandin E2 (PGE2) production
in the absence or the presence of IL-1 in human osteo-
arthritic chondrocytes. We provide evidence that 15d-PGJ2
exerts opposite regulatory effects: it suppressed the IL-1-
induced COX-2 expression and PGE2 production, but in the
absence of IL-1, it up-regulated COX-2 without any true
effect on the synthesis of PGE2.Materials and methodsReceived 20 May 2002; revision accepted 17 July 2002.
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Human cartilage specimens were obtained from osteo-
arthritic patients who had undergone total knee joint
replacement. Diagnosis was established according to the
American College of Rheumatology criteria10. The osteo-
arthritic cartilage from tibial plateaus was obtained under
aseptic conditions and carefully dissected from the
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COX-2 level was determined using Western blot analysis
and performed as previously described7. Cells were lysed
in RIPA buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl,
2 mM EDTA, 1 mM PMSF, 10 g/ml each of aprotinin,
leupeptin, and pepstatin, 1% NP-40, 1 mM sodium
orthovanadate, and 1 mM NaF), the protein was deter-
mined using the bicinchoninic acid method (Pierce,
Rockford, IL), and Western immuoblot was performed.
Briefly, cellular protein extract was subjected to 12%
sodium dodecyl sulfate (SDS)-polyacrylamide gel electo-
phoresis under reducing conditions and transferred
onto nitrocellulose membranes (Amersham Pharmacia
Biotech, Baie d’Urfe´, Quebec, Canada). After blocking with
SuperBlock blocking buffer (Pierce) in Tris buffered saline
(20 mM Tris–HCl, 150 mM NaCl, pH 7.5) and washing, the
membranes were incubated overnight at 4°C with primary
antibody in the blocking buffer as above. The antibody was
a polyclonal antihuman COX-2 (Cayman Chemical Co.)
and was used at a dilution of 1:5000. A second antirabbit
antibody (horseradish peroxidase conjugated), 1:20 000
dilution (Pierce), was subsequently incubated with the
membrane for 1 h at room temperature and then washed
extensively with TTBS (0.1% Tween® 20, 20 mM Tris-HCl,
150 mM NaCl pH 7.5) at room temperature. Following
incubation with SuperSignal Ultra Chemiluminescent
substrate (Pierce), membranes were prepared for auto-
radiogaphy and exposed to Kodak X-Omat film (Eastman
Kodak Ltd, Rochester, NY). The autoradiographs were
scanned using ChemiImager 4000 imaging system (Alpha
Innotech, San Leandro, CA); the values were calculated as
relative units, and 1 unit was given to the untreated control.PGE2 DETERMINATION
PGE2 was determined using a PGE2 enzyme immu-
noassay kit from Cayman Chemical (Ann Arbor, MI). This
assay uses the competition between PGE2 and a PGE2-
acetylcholinesterase conjugate (PGE2 tracer) for a limited
amount of PGE2 monoclonal antibody. The sensitivity was
9 pg/ml.DATA ANALYSIS
Data are expressed as the mean±S.E.M. of independent
specimens. Statistical analysis was performed by theStudent two-tailed paired t-test. A difference of 0.05 was
considered significant.Results and Discussion
As illustrated at Fig. 1(a), COX-2 expression was barely
detectable in unstimulated cells but superinduced in the
presence of IL-1. The addition of 15d-PGJ2 suppressed
the IL-1-induced COX-2 expression in a dose-dependent
manner. Densitometric analysis (Alpha-Innotech) revealed
that 10 M 15d-PGJ2 reduced the IL-1-induced COX-2
production by 72%. To establish whether the decrease in
COX-2 levels corresponded with a decrease in COX
activity, PGE2 levels were also determined. As for COX-2,
PGE2 synthesis was increased by IL-1 and dose-
dependently inhibited with 15d-PGJ2 [Fig. 1(b)]. At 10 M,
15d-PGJ2 abrogated (inhibition of 93%) the IL-1-induced
PGE2.
In the presence of IL-1, COX-2 levels were not com-
pletely reduced, even at the highest 15d-PGJ2 concen-
tration used, while PGE2 synthesis was completely
blocked. This suggests that 15d-PGJ2 may have the possi-
bility to induce COX-2 expression. Thus, we investigated
the effect of 15d-PGJ2 on COX-2 and PGE2 production in
the absence of any COX-2 inducer. Our results indicate
that the addition of 15d-PGJ2 alone dose-dependently
up-regulates COX-2 expression in osteoarthritic chondro-
cytes [Fig. 1(c)]. Surprisingly, 15d-PGJ2 did not affect PGE2
synthesis [Fig. 1(d)]. This did not reflect a lack of AA.
Indeed, a complementary experiment in which 10 M of AA
was added at the beginning of the incubation period led to
an identical 15d-PGJ2 effect, although the PGE2 level in the
AA control was elevated by 1.7-fold when compared to the
control (cells not treated with AA) (data not illustrated).
In this study, we demonstrated that 15d-PGJ2 inhibits
IL-1-induced COX-2 production in human osteoarthritic
chondrocytes. The IC50 value was about 1-5 M, which is
consistent with its kd for PPAR, suggesting that the effect
of 15d-PGJ2 is mediated through PPAR. This may explain
the earlier observations that dietary n-3 fatty supplementa-
tion results in a substantial improvement in clinical status in
patients with arthritic diseases11,12 as these fatty acids are
bona fide ligands of PPAR. The involvement of PPAR in
the effect of 15d-PGJ2 is further supported by findings from
promoter-reporter assays where 15d-PGJ2 was shown to
inhibit LPS- or PMA-stimulated COX-2 promoter activity in
a PPAR dependent manner. This inhibition occurred
through antagonizing the transcriptional activity of NF-B
and AP-113,14.
However, results from other studies, suggest that 15d-
PGJ2 may also act via a PPAR-independent pathway. For
example, 15d-PGJ2 was recently found to inhibit NF-B by
a covalent modification of a cystein residue within its
activation loop in IB kinase beta15. In addition, PPAR
ligands, including 15d-PGJ2, suppress the induction of
COX-2 in PPAR −/− macrophages16. It is also possible
that 15d-PGJ2 might inhibit IL-1-induced PGE2 syn-
thesis by modulating other enzymes (such as PLA2) or
signal transduction pathways that regulate prostaglandin
metabolism.
We also show in this study that 15d-PGJ2 alone induced
the expression of COX-2 protein. This is in agreement with
our previous study, where we showed that PPAR and 
activators induce COX-2 expression at the protein and
mRNA level in human synovial fibroblasts17. However, we
did examine the effect of 15d-PGJ on PGE synthesis17.underlying bone as described7. Cartilage was dissected,
washed thoroughly, and cells were released as previ-
ously described7. The cells were cultured at 37°C in
Dulbecco Modified Eagle Medium (DMEM) (Gibco, BRL-
Life Technologies; Burlington, Ontario, Canada) contain-
ing 0.5% fetal calf serum (Gibco-BRL) in a humidified
atmosphere of 5% CO2/95% air. At confluence, cells
were detached and passaged once in order to keep the
phenotype.
Three sets of experiments were performed. Firstly, cells
(N=4) were pre-incubated for 15 min in the absence or
presence of 15d-PGJ2 (1, 5, 10 M) (Cayman Chemical
Co., Ann Arbor, MI) followed by the addition of rhuIL-1
(100 pg/ml) (R & D Systems, Minneapolis, MN) for 18 h. In
the second set, cells (N=4) were incubated for 18 h only
with 15d-PGJ2 at the above concentrations. Finally, cells(N=3) were incubated for 18 h with 15d-PGJ2 and 10 M
arachidonic acid (AA) (Cayman Chemical).2 2
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expression and inhibit IL-1-induced COX-2 are in a similar
range. Thus, the magnitude of the induction of COX-2
expression by 15d-PGJ2 might have been even stronger
if there had been no concomitant inhibition of COX-2
expression.
The mechanism by which 15d-PGJ2 favors COX-2 pro-
tein accumulation remains to be elucidated. Meade et al.18
analysed the sequence of the human COX-2 promoter
and identified a peroxisome proliferator response element
(PPRE) consensus site at approximately 3900 bases
upstream of the translational start site and demonstrated
that this site is responsible for the enhancement of COX-2
expression in response to 15d-PGJ2. However, these
authors did not determine whether PGE2 synthesis paral-
lels the increase in COX-2 expression. In our system, we
found that 15d-PGJ2 induced COX-2 expression while it
had no effect on PGE2 synthesis. Possible explanations
may be by stabilizing the protein structure or by inducing a
decrease in the synthesis of agents that favor COX-2
degradation. In this context, the destabilizing effect of PGE2
and cAMP stimulants on COX-2 has been reported in
macrophages19. Ultimately, it is possible that the COX-2
enzyme induced by 15d-PGJ2 is active, but for an unknown
reason its activity is directed toward the synthesis of
prostaglandins other than PGE2, such as PGD2. This is
supported by the finding of Gilroy et al.20, who showed that
inflammation resolution in carrageenin-induced pleurisy in
rats is associated with a reduced synthesis of PGE and2an increase in the levels of PGD2 and its dehydration
metabolite 15d-PGJ2.
The regulation of COX-2 expression and activity is
complex as evidenced by 15d-PGJ2 inducing an increase
in COX-2 expression but without concomitant PGE2 syn-
thesis. Conversely, 15d-PGJ2 inhibits IL-1-induced COX-2
expression as well as PGE2 synthesis. It would be import-
ant to determine whether 15d-PGJ2 exerts its dual effects
through different signal transduction pathways and whether
15d-PGJ2 acts on COX-2 enzyme activity.Acknowledgments
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Yampolsky for her secretarial assistance.Fig. 1. Effect of 15d-PGJ2 on the basal and IL-1-induced COX-2 expression and PGE2 production in human osteoarthritic chondrocytes.
Cells were pre-incubated for 15 min in the presence of increasing concentrations of 15d-PGJ2 and incubated in the presence (a), (b) or
absence (c), (d) of IL-1 for 18 h. (a), (c) Cell proteins were extracted and 5 g (a) and 20 g (c) analysed by Western analysis for COX-2.
(b), (d) PGE2 levels were determined in the conditioned culture medium. Values are the mean±S.E.M.; P values (vs control) were determined
by Student two-tailed paired t-test.References
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